Affiliation:
1. Department of Pediatrics, Columbia University Medical Center, New York, NY; and
2. Medical Faculty, Pediatric Hematology and Oncology, Technical University Dresden, Dresden, Germany
Abstract
AbstractEvidence-based recommendations have been established for treatment of chronic myeloid leukemia (CML) in adults treated with tyrosine kinase inhibitors (TKIs), but the rarity of this leukemia in children and adolescents makes it challenging to develop similar recommendations in pediatrics. In addition to imatinib, which was approved for pediatric CML in 2003, the second-generation TKIs dasatinib and nilotinib were recently approved for use in children, expanding the therapeutic options and pushing allogeneic stem cell transplantation to a third-line treatment of most pediatric cases. Yet, without sufficient data on efficacy and safety specific to pediatric patients, the selection of a TKI continues to rely on clinical experience in adults. Here, we present 4 case scenarios highlighting common yet challenging issues encountered in the treatment of pediatric CML (suboptimal response, poor treatment adherence, growth retardation, and presentation in advanced phases). Limited experience with very young children, the transition of teenagers to adult medicine, and the goal of achieving treatment-free remission for this rare leukemia are additional significant obstacles that require further clinical investigation through international collaboration.
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Reference97 articles.
1. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach;Hijiya;Blood,2016
2. Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions;Hijiya;Pediatr Clin North Am,2015
3. Differences among young adults, adults and elderly chronic myeloid leukemia patients;Castagnetti;Ann Oncol,2015
4. advanced phases at diagnosis of childhood chronic myeloid leukemia: the experience of the International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped Study) [abstract];Millot;Blood,2017
5. Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia;Krumbholz;Genes Chromosomes Cancer,2012
Cited by
87 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献